Wall Street Hates These 2 Biotechs

Brean Capital has come out today with a pair of substantial downgrades. First, it has downgraded VIVUS (NASDAQ: VVUS  ) , maker of the obesity drug Qsymia, to a sell, and set the price target at a painful $7 per share. This is a 50% downside from yesterday's $14.32; the stock fell 5% as a result. Brean also downgraded Celsion (NASDAQ: CLSN  ) to a sell, placing the price target at an astonishing $1 per share. Celsion is also down over 5% on the news. In this video, Motley Fool health-care analyst David Williamson tells us what was behind these killer downgrades, and whether investors should be worried.

The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including one developed by VIVUS, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense, but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health-care writer on the job, so make sure to secure a copy today by clicking here now.


Read/Post Comments (4) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 17, 2013, at 5:01 PM, DAG1996MF wrote:

    The Street loves Celsion ... one clueless analyst at one of the most useless research firms on The Street hates Celsion. Just look at the idiot's track record.

  • Report this Comment On January 17, 2013, at 5:20 PM, Hope4GoodFuture wrote:

    Mr. Williamson,

    I'm not sure exactly what you view your job to be? It would be nice if, from time to time, you do a little more than simply regurgitate what other people have said. Simply restating what Brean Capital said doesn't add much value, unless people use Motley Fool as their sole source of news (Brean Capital's downgrade was all over the press today). What may have been helpful would have been some insight or analysis. For example, why did Brean Capital have a BUY rating on CLSN with a target of $7 up until today, and suddenly switch to a SELL rating with a target of $1 ? At $7 BUY, CLSN was a binary event company with PFS as its endpoint. Nothing has changed since Brean set this price target. It would have been nice if you had pointed this out. Was Brean right before and wrong now, or right now and wrong before? Either way, doesn't Brean have some explaining to do? Did the analyst have a bad dream, or a moment of Zen? What is the role of an analyst that is widely reported and potentially market moving? What standards should they be held up to? Did this analyst adhere to any standard? There is a story here, but not the one you "reported".

  • Report this Comment On January 17, 2013, at 5:47 PM, earthunit wrote:

    LOL. "Wall Street hates these two." Or, your crony buddies hate losing money on their short positions on these two? I'll pick the second choice.

    Hey man, get a real job. Try doing something constructive.

  • Report this Comment On January 17, 2013, at 7:49 PM, hsawaknow wrote:

    @ hope4goodfuture

    I assertively second that...

Add your comment.

DocumentId: 2202548, ~/Articles/ArticleHandler.aspx, 7/31/2014 1:49:59 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement